Health & Fitness
Health and Fitness
Health and Fitness
Wed, June 17, 2009
Tue, June 16, 2009
Mon, June 15, 2009
Fri, June 12, 2009
Thu, June 11, 2009
Wed, June 10, 2009 Cancer Therapeutics : Cancer Therapeutics, Inc.'s Partner NanoTherapies, Inc. Utilizes Revolutionary Solution for Disrupting an
SALT LAKE CITY, UT--(Marketwire - June 10, 2009) - Cancer Therapeutics, Inc. (
NanoTherapies has sole license and patent protection for the fundamental use of calcium phosphate nanoparticles in medical applications for the treatment and detection of blood cancers (all forms of leukemia). NanoTherapies has all rights to manufacturing technologies and intellectual property required to produce pharmaceutical quality drugs at the scale and yield needed for commercial viability.
Calcium phosphate is a major component of bones. NanoTherapies' calcium phosphate NanoJackets clear the kidneys and liver without impact. They exit the body via the colon, and their chemical properties enable them to circulate in the bloodstream for prolonged periods yet dissolve in diseased cells, thereby releasing the drug. Metallic, silicon and carbon based nanoparticles cannot make the same claims regarding biocompatibility for humans nor do they have the chemical or physical properties that allow effective drug release in diseased cells.
Patient benefits from drugs jacketed with calcium phosphate nanoparticles are immense. Early lab studies show a ten-fold reduction in toxicity with a seven-fold increase in effectiveness for drugs delivered using NT's technology. This means dramatically reduced side-effects owing to the severe toxicity of cancer drugs and increased effectiveness because the half-life of the drug is increased from minutes to hours. Most cancer drugs kill all the cells they contact and dissipate in less than thirty minutes. NT's nanojackets encapsulate the drugs for up to thirty hours before being cleared from the body or until the nanoparticle enters a cancerous cell and release the drug. NT's technology moves drug delivery strategies from carpet-bombing to smart-bombing with the corresponding dramatic decrease in collateral damage.
In the same way NT's nanoparticles deliver drugs to cancerous cells they can also transport imaging dyes that fluoresce under near infrared light to reveal cancerous cells. Imaging cancer at the cellular level enables new methods of early detection of cancer as well as post-treatment and post-operative evaluation.
About Cancer Therapeutics, Inc.:
Cancer Therapeutics, Inc. is a biotechnology business incubator, with a specific emphasis on disruptive treatments and nanotechnology. It seeks out disruptive cancer research and technology opportunities to invest in, develop, and commercialize. The end result will be therapies, treatments, and pharmaceuticals targeted at more efficiently and effectively attacking cancer. CTI seeks partners to co-develop drugs in various stages in our pipeline.
Safe Harbor: This letter contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainty, including without limitation, the ability of the Company to successfully implement its turnaround strategy, changes in costs of raw materials, labor, and employee benefits, as well as general market conditions, competition and pricing. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this letter will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as representation by the Company or any other person that the objectives and plans of the Company will be achieved. In assessing forward-looking statements included herein, readers are urged to carefully read those statements. When used in the Annual Report on Form 10-K, the words "estimate," "anticipate," "expect," "believe," and similar expressions are intended to be forward-looking statements.
